EPI-SK 14, a phase I/II study with Artemether has successfully been
completed. The data demonstrate a clinically relevant and statistically
significant regression of SK lesions in size, color and texture.
Regression continued markedly after treatment stop. The study results
have been published online in the British Journal of Dermatology.
EPI-SK17 has been selected as lead product candidate based on
properties which distinguish it from other artemisinin derivatives
tested, including greater potency, and shorter duration of treatment.
The product is about to enter phase IIb clinical development.